Pepsinogen I and II, Gastrin and Cag A Serum Levels in Shiraz
Seyedeh Azra Shamsdin1, Mehdi Saberifiroozi2, Davood Mehrabani1
1Gastroenterohepatology Research Center (GEHRC), Nemazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
Abstract:
BACKGROUND Despite the similar rate of HP infection, the rate of gastric cancer (GC) differs in different regions of the country. There are conflicting reports for using a panel of serologic tests such as pepsinogens I, II (PG I and PG II), and gastrin for population screening. We designed this study to assess healthy appearing adults in Shiraz, southern Iran in order to evaluate the correlation of these serological tests with demographics and lifestyle in a region with a low rate of gastric malignancy. METHODS In a population-based study, 846 out of 1978 subjects who were selected by cluster random sampling based on postal code division in Shiraz agreed to participate in the present study. A questionnaire that included age, gender, weight and height, lifestyle such as physical activity, smoking and the use of nonsteroidal anti inflammatory drugs (NSAIDs) was completed. A blood sample was taken after overnight fasting for measurements of PG I, PG II and Cag A status by enzyme-linked immunosorbant assay (ELISA). Gastrin level was measured by radioimmunoassay (RIA). RESULTS The study included 305 men and 541 women. Their mean age was 50.53+11.4 (range: 35-99 years). The level of PG I was significantly more in males than females (116.6±57.1 vs. 103.1±55.8, p < 0.001), lower in older age groups (p = 0.01), and rural compared with urban residents (110.3+55.7 vs. 100.2+58.1, p = 0.02). The serum level of PG II was less in obese subjects (p = 0.5). There was no significant correlation between PG I, PG II, smoking, NSAID use and activity. Gastrin level were not correlated with any of the demographic characteristics. The level of Cag A was significantly different between males and females (30.5±37 vs. 37.7±41.7, p < 0.001), more in older subjects (p = 0.007) and non smokers (p = 0.001). The serum levels of PG I and PG I/PG II ratio decreased significantly in subjects with positive Cag A serology (p < 0.05). The ratio of PG I/PG II was lower than 3 in 35 (4.1%) subjects. CONCLUSION In this area, the PG I/PG II ratio is less than 3 in 4% of subjects of which most are positive for Cag A serology and older than 50. We recommend comparison of these findings with high GC mortality regions.
More Related Videos
Related Concept Videos
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
Gastritis II: Pathophysiology
Serum Laboratory Studies, Stool Test, Breath Test
Gastritis-II: Pathophysiology
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...


